FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2580821712> ?p ?o ?g. }

• W2580821712 endingPage "2084" @default.
• W2580821712 startingPage "2075" @default.
• W2580821712 abstract "Although the BTK inhibitor ibrutinib has transformed the management of patients with chronic lymphocytic leukemia (CLL), it does not induce substantial apoptosis in vitro, and as such the mechanisms underlying its ability to kill CLL cells are not well understood. Acalabrutinib, a more specific BTK inhibitor now in development, also appears to be highly effective in CLL, but the connection of its mechanism with CLL cell death is also unclear. Using dynamic BH3 profiling, we analyzed alterations in the function of the mitochondrial apoptotic pathway induced by ibrutinib and acalabrutinib. We studied CLL patient samples treated ex vivo with both drugs, as well as primary samples from CLL patients on clinical trials of both drugs. We found that BTK inhibition enhances mitochondrial BCL-2 dependence without significantly altering overall mitochondrial priming. Enhancement of BCL-2 dependence was accompanied by an increase in the pro-apoptotic protein BIM. In contrast, treatment with the selective BCL-2 inhibitor venetoclax enhanced overall mitochondrial priming without increasing BCL-2 dependence. Pre-treatment of CLL cells with either BTK inhibitor, whether ex vivo or in vivo in patients, enhanced killing by venetoclax. Our data suggest that BTK inhibition enhances mitochondrial BCL-2 dependence, supporting the ongoing development of clinical trials combining BTK and BCL-2 inhibition." @default.
• W2580821712 created "2017-02-03" @default.
• W2580821712 creator A5009506175 @default.
• W2580821712 creator A5016570475 @default.
• W2580821712 creator A5022857112 @default.
• W2580821712 creator A5063755644 @default.
• W2580821712 creator A5065668271 @default.
• W2580821712 creator A5088894119 @default.
• W2580821712 date "2017-01-23" @default.
• W2580821712 modified "2023-10-15" @default.
• W2580821712 title "Bruton’s tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia" @default.
• W2580821712 cites W1972763059 @default.
• W2580821712 cites W1982254984 @default.
• W2580821712 cites W1986924929 @default.
• W2580821712 cites W2011950935 @default.
• W2580821712 cites W2038421089 @default.
• W2580821712 cites W2047115666 @default.
• W2580821712 cites W2064381013 @default.
• W2580821712 cites W2067064694 @default.
• W2580821712 cites W2071549499 @default.
• W2580821712 cites W2071773206 @default.
• W2580821712 cites W2089065768 @default.
• W2580821712 cites W2097007474 @default.
• W2580821712 cites W2097290512 @default.
• W2580821712 cites W2098265722 @default.
• W2580821712 cites W2108206643 @default.
• W2580821712 cites W2140052555 @default.
• W2580821712 cites W2140395974 @default.
• W2580821712 cites W2153923291 @default.
• W2580821712 cites W2165056381 @default.
• W2580821712 cites W2172242534 @default.
• W2580821712 cites W2192121806 @default.
• W2580821712 cites W2316021978 @default.
• W2580821712 cites W2338693134 @default.
• W2580821712 cites W2339774970 @default.
• W2580821712 cites W2369297677 @default.
• W2580821712 doi "https://doi.org/10.1038/leu.2017.32" @default.
• W2580821712 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/5555835" @default.
• W2580821712 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28111464" @default.
• W2580821712 hasPublicationYear "2017" @default.
• W2580821712 type Work @default.
• W2580821712 sameAs 2580821712 @default.
• W2580821712 citedByCount "134" @default.
• W2580821712 countsByYear W25808217122017 @default.
• W2580821712 countsByYear W25808217122018 @default.
• W2580821712 countsByYear W25808217122019 @default.
• W2580821712 countsByYear W25808217122020 @default.
• W2580821712 countsByYear W25808217122021 @default.
• W2580821712 countsByYear W25808217122022 @default.
• W2580821712 countsByYear W25808217122023 @default.
• W2580821712 crossrefType "journal-article" @default.
• W2580821712 hasAuthorship W2580821712A5009506175 @default.
• W2580821712 hasAuthorship W2580821712A5016570475 @default.
• W2580821712 hasAuthorship W2580821712A5022857112 @default.
• W2580821712 hasAuthorship W2580821712A5063755644 @default.
• W2580821712 hasAuthorship W2580821712A5065668271 @default.
• W2580821712 hasAuthorship W2580821712A5088894119 @default.
• W2580821712 hasBestOaLocation W25808217122 @default.
• W2580821712 hasConcept C100701293 @default.
• W2580821712 hasConcept C190283241 @default.
• W2580821712 hasConcept C203014093 @default.
• W2580821712 hasConcept C207001950 @default.
• W2580821712 hasConcept C26291073 @default.
• W2580821712 hasConcept C2777938653 @default.
• W2580821712 hasConcept C2778461978 @default.
• W2580821712 hasConcept C2779675984 @default.
• W2580821712 hasConcept C2779878957 @default.
• W2580821712 hasConcept C42362537 @default.
• W2580821712 hasConcept C502942594 @default.
• W2580821712 hasConcept C54355233 @default.
• W2580821712 hasConcept C55493867 @default.
• W2580821712 hasConcept C59822182 @default.
• W2580821712 hasConcept C62478195 @default.
• W2580821712 hasConcept C71924100 @default.
• W2580821712 hasConcept C81444415 @default.
• W2580821712 hasConcept C86803240 @default.
• W2580821712 hasConcept C90059517 @default.
• W2580821712 hasConcept C95444343 @default.
• W2580821712 hasConcept C98274493 @default.
• W2580821712 hasConceptScore W2580821712C100701293 @default.
• W2580821712 hasConceptScore W2580821712C190283241 @default.
• W2580821712 hasConceptScore W2580821712C203014093 @default.
• W2580821712 hasConceptScore W2580821712C207001950 @default.
• W2580821712 hasConceptScore W2580821712C26291073 @default.
• W2580821712 hasConceptScore W2580821712C2777938653 @default.
• W2580821712 hasConceptScore W2580821712C2778461978 @default.
• W2580821712 hasConceptScore W2580821712C2779675984 @default.
• W2580821712 hasConceptScore W2580821712C2779878957 @default.
• W2580821712 hasConceptScore W2580821712C42362537 @default.
• W2580821712 hasConceptScore W2580821712C502942594 @default.
• W2580821712 hasConceptScore W2580821712C54355233 @default.
• W2580821712 hasConceptScore W2580821712C55493867 @default.
• W2580821712 hasConceptScore W2580821712C59822182 @default.
• W2580821712 hasConceptScore W2580821712C62478195 @default.
• W2580821712 hasConceptScore W2580821712C71924100 @default.
• W2580821712 hasConceptScore W2580821712C81444415 @default.
• W2580821712 hasConceptScore W2580821712C86803240 @default.
• W2580821712 hasConceptScore W2580821712C90059517 @default.

• next